Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
April 08, 2024 11:15 ET
|
Imbria Pharmaceuticals Inc.
– Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated – – Results support initiation of the Phase 3 FORTITUDE-HCM...
Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)
March 25, 2024 08:00 ET
|
Imbria Pharmaceuticals Inc.
– Ninerafaxstat Phase 2 clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM) is complete;Phase 3 to be initiated in the 2H 2024 – BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Imbria...
Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
November 07, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
– The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement, compared...
Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy
December 05, 2022 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...